LATEST NEWS

Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.